Jeffrey Duchemin

All filings by Jeffrey Duchemin on record concern Harvard Bioscience Inc. We count 40 filings; the first trade dates from 30 June 2014 and the latest from 7 July 2019.

Market trades split into 4 purchases (€125k) and 12 sales (€1.4M). On balance, insiders were net sellers of €1.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 14 share grants and 3 option exercises. In 2019 alone, the filings show no purchases and 3 sales.

The median purchase comes to €32k. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 33% of cases; the median change was -14.7%. Past outcomes like these are no guarantee of what comes next.

The record was last updated on 9 July 2019 with a transaction in Harvard Bioscience Inc. The most recent open-market purchase was published on 13 June 2017, 3,436 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.